VX-680/MK-0457 - Aurora kinase inhibitor oncolytic

被引：8

作者：

Wang, Y. ^{[1
]}

Serradell, N. ^{[1
]}

机构：

[1] Prous Sci, E-08080 Barcelona, Spain

来源：

DRUGS OF THE FUTURE | 2007年 / 32卷 / 02期

关键词：

D O I：

10.1358/dof.2007.032.02.1076496

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

VX-680/MK-0457 is a small-molecule Aurora kinase inhibitor with inhibition constants (K(i)) of 0.6, 18 and 4.6 nM for Aurora kinase A, B and C, respectively; it also inhibits Flt-3 and AN kinases, particularly mutant forms. The compound displays potent antitumor activity in a broad range of cancer cell lines and is well tolerated in preclinical studies. A phase I clinical trial of VX-680/MK-0457 was carried out in patients with chronic myeloid leukemia (CML) or acute lymphocytic leukemia (ALL) with the T315l Bcr-Abl resistance mutation and patients with refractory JAK2-positive myeloproliferative disease. VX-680/MK-0457 demonstrated encouraging antitumor activity and a good overall safety profile.

引用

页码：144 / 147

页数：4

共 50 条

[1] Activity of the aurora kinase inhibitor MK-0457 (VX-680) in combination with taxotere
Hoover, R. R.
Harding, M. W.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[2] The discovery of the potent aurora inhibitor MK-0457 (VX-680)
Bebbington, David
Binch, Hayley
Charrier, Jean-Damien
Everitt, Simon
Fraysse, Damien
Golec, Julian
Kay, David
Knegtel, Ronald
Mak, Chau
Mazzei, Francesca
Miller, Andrew
Mortimore, Michael
O'Donnell, Michael
Patel, Sanjay
Pierard, Francoise
Pinder, Joanne
Pollard, John
Ramaya, Sharn
Robinson, Daniel
Rutherford, Alistair
Studley, John
Westcott, James
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (13) : 3586 - 3592
[3] The aurora kinase inhibitor MK-0457 (VX-680) demonstrates anticancer activity alone or in combination with clocetaxel (Dtx)
Hoover, R. R.
Haregewoin, A.
Harding, M. W.
EJC SUPPLEMENTS, 2007, 5 (04): : 66 - 67
[4] Synergistic activity of the aurora kinase inhibitor MK-0457 (VX-680) with idarubicin, Ara-C, and inhibitors of BCR-ABL.
Hoover, Russell R.
Harding, Matthew W.
BLOOD, 2006, 108 (11) : 403A - 403A
[5] Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia
Donato, Nicholas J.
Fang, Dexing
Sun, Hanshi
Giannola, Diane
Peterson, Luke F.
Talpaz, Moshe
BIOCHEMICAL PHARMACOLOGY, 2010, 79 (05) : 688 - 697
[6] Profiling of kinase inhibitors Lapatinib, VX-680/MK-0457, Sorafenib, Sunitinib, Erlotinib, Gefitinib, and Vatalanib in cellular phosphorylation assays
Ehlert, Jan
Mutschler, Bettina
Mueller, Melanie
Feger, Daniel
Umber, Sarah
Weber, Holger
Ziegler, Daniela
Schaechtele, Christoph
Kubbutat, Michael
CANCER RESEARCH, 2009, 69
[7] Cotreatment with Vorinostat Enhances Activity of MK-0457 (VX-680) against Acute and Chronic Myelogenous Leukemia Cells
Fiskus, Warren
Wang, Yongchao
Joshi, Rajeshree
Rao, Rekha
Yang, Yonghua
Chen, Jianguang
Kolhe, Ravindra
Balusu, Ramesh
Eaton, Kelly
Lee, Pearl
Ustun, Celalettin
Jillella, Anand
Buser, Carolyn A.
Peiper, Stephen
Bhalla, Kapil
CLINICAL CANCER RESEARCH, 2008, 14 (19) : 6106 - 6115
[8] In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma
Alexander Dewerth
Timo Wonner
Justus Lieber
Verena Ellerkamp
Steven W. Warmann
Jörg Fuchs
Sorin Armeanu-Ebinger
Pediatric Surgery International, 2012, 28 : 579 - 589
[9] In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma
Dewerth, Alexander
Wonner, Timo
Lieber, Justus
Ellerkamp, Verena
Warmann, Steven W.
Fuchs, Joerg
Armeanu-Ebinger, Sorin
PEDIATRIC SURGERY INTERNATIONAL, 2012, 28 (06) : 579 - 589
[10] VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma
Li, Yan
Zhang, Zhong-Fa
Chen, Jindong
Huang, Dan
Ding, Yan
Tan, Min-Han
Qian, Chao-Nan
Resau, James H.
Kim, Hyung
Teh, Bin Tean
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2010, 2 (03): : 296 - 308

← 1 2 3 4 5 →